Evidence map›Paper›PMID 29698955›Full record

ArticleAmerican journal of nephrology2018

Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure.

Andrew Bostom, Dominik Steubl, Pranav S Garimella, Nora Franceschini, Mary B Roberts, Andreas Pasch, Joachim H Ix, Katherine R Tuttle, Anastasia Ivanova, Theresa Shireman and 7 more

Abstract readControlled Clinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Uromodulin biology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  8. Article
  9. Review
  10. Role of Uromodulin in Salt-Sensitive Hypertension.Hypertension (Dallas, Tex. : 1979) · 2022
    Review
  11. Urine Uromodulin and Genetics of its Variation.Journal of the American Society of Nephrology : JASN · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 4 countries.

Andrew BostomCenter For Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, USA.
Dominik SteublKlinikum rechts der Isar, Technische Universität, München, Germany.
Pranav S GarimellaDivision of Nephrology-Hypertension, Department of Medicine, University of California, San Diego, California, USA.
Nora FranceschiniDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Mary B RobertsCenter For Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, USA.
Andreas PaschUniversity of Bern, Bern, Switzerland.
Joachim H IxDivision of Nephrology-Hypertension, Department of Medicine, University of California, San Diego, California, USA.
Katherine R TuttleProvidence Medical Research Center, University of Washington, Spokane, Washington, USA.
Anastasia IvanovaDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Theresa ShiremanCenter for Gerontology and Healthcare Research, Brown University, Providence, Rhode Island, USA.
S Joseph KimDivision of Nephrology and the Kidney Transplant Program, Toronto General Hospital, Toronto, Ontario, Canada.
Reginald GohhDivision of Hypertension and Kidney Diseases, Department of Medicine, Rhode Island Hospital, Providence, Rhode Island, USA.
Daniel E WeinerDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
Andrew S LeveyDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
Chi-Yuan HsuDivision of Nephrology, University of California-San Francisco, San Francisco, California, USA.
John W KusekNational Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Charles B EatonDepartment of Family Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Brown University · USMemorial Hospital of Rhode Island · USTufts Medical Center · USUniversity of California, San Diego · USUniversity of North Carolina at Chapel Hill · USNational Institute of Diabetes and Digestive and Kidney Diseases · USProvidence Regional Medical Center Everett · USRhode Island Hospital · USTechnical University of Munich · DEToronto General Hospital · CAUniversity of Bern · CHUniversity of California, San Francisco · US

Funding

Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialU01DK061700 · NIDDK · TUFTS MEDICAL CENTER · PI BOSTOM, ANDREW G. · 2001 to 2011
$29.0M
NIDDK NIH HHS U01 DK061700
6 · The paper itself

Abstract

backgroundUromodulin is a kidney-derived glycoprotein and putative tubular function index. Lower serum uromodulin was recently associated with increased risk for kidney allograft failure in a preliminary, longitudinal single-center -European study involving 91 kidney transplant recipients (KTRs).

methodsThe Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial is a completed, large, multiethnic controlled clinical trial cohort, which studied chronic, stable KTRs. We conducted a case cohort analysis using a randomly selected subset of patients (random subcohort, n = 433), and all individuals who developed kidney allograft failure (cases, n = 226) during follow-up. Serum uromodulin was determined in this total of n = 613 FAVORIT trial participants at randomization. Death-censored kidney allograft failure was the study outcome.

resultsThe 226 kidney allograft failures occurred during a median surveillance of 3.2 years. Unadjusted, weighted Cox proportional hazards modeling revealed that lower serum uromodulin, tertile 1 vs. tertile 3, was associated with a threefold greater risk for kidney allograft failure (hazards ratio [HR], 95% CI 3.20 [2.05-5.01]). This association was attenuated but persisted at twofold greater risk for allograft failure, after adjustment for age, sex, smoking, allograft type and vintage, prevalent diabetes mellitus and cardiovascular disease (CVD), total/high-density lipoprotein cholesterol ratio, systolic blood pressure, estimated glomerular filtration rate, and natural log urinary albumin/creatinine: HR 2.00, 95% CI (1.06-3.77).

conclusionsLower serum uromodulin, a possible indicator of less well-preserved renal tubular function, remained associated with greater risk for kidney allograft failure, after adjustment for major, established clinical kidney allograft failure and CVD risk factors, in a large, multiethnic cohort of long-term, stable KTRs.

Indexed as

Kidney TransplantationAdultAllograftsCohort StudiesFemaleHumansMaleMiddle AgedRenal InsufficiencyUromodulinUMOD protein, humanUromodulinKidney allograft failureKidney transplantationSerum uromodulin

Identifiers

PMID29698955
PMCPMC6754623
OpenAlexW2801462762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.